Document Detail


Preterm birth rates in a prematurity prevention clinic after adoption of progestin prophylaxis.
MedLine Citation:
PMID:  24463661     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate whether progestin prophylaxis influenced the odds of recurrent spontaneous preterm birth among pregnant women with a previous preterm birth.
METHODS: A retrospective cohort study was performed evaluating outcomes of pregnant women with one or more previous preterm births who received prenatal care in a single academic prematurity clinic. Care algorithms were determined and revised by a single supervising physician. Progestin prophylaxis was adopted in 2004 with accelerated access to the first clinic visit adopted in 2008. Rates of preterm birth before 37, 35, and 32 weeks of gestation were compared over time.
RESULTS: One thousand sixty-six women with a history of one or more spontaneous preterm births received care in the prematurity clinic and were delivered between January 1, 1998, and June 30, 2012. The gestational age at initiation of prenatal care declined significantly after adoption of an accelerated appointment process (median of 19.1 weeks before 2003, 16.2 weeks from 2004 to 2007, and 15.2 weeks from 2008 to 2012, P<.01), and progestin use increased from 50.8% in 2004-2007 to 80.3% after 2008 (P<.01). After adjustment for race, smoking, cerclage, and number of prior preterm deliveries, we noted a statistically significant decreased odds of spontaneous preterm birth in years 2008-2012 compared with 1998-2007 before 37 (adjusted odds ratio [OR] 0.75, 95% confidence interval [CI] 0.58-0.97) and 35 (adjusted OR 0.70, 95% CI (.52-0.94) weeks of gestation.
CONCLUSION: Adoption of prophylactic progestin treatment was associated with a decreased odds of recurrent preterm birth before 37 or 35 weeks of gestation after adoption of an aggressive program to facilitate early initiation of progestin treatment.
LEVEL OF EVIDENCE: II.
Authors:
Kara B Markham; Hetty Walker; Courtney D Lynch; Jay D Iams
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  123     ISSN:  1873-233X     ISO Abbreviation:  Obstet Gynecol     Publication Date:  2014 Jan 
Date Detail:
Created Date:  2014-01-27     Completed Date:  2014-03-18     Revised Date:  2014-04-01    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  34-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Female
Humans
Hydroxyprogesterones / therapeutic use*
Infant, Newborn
Infant, Premature
Ohio / epidemiology
Pregnancy
Premature Birth / epidemiology,  prevention & control*
Progestins / therapeutic use*
Retrospective Studies
Chemical
Reg. No./Substance:
0/Hydroxyprogesterones; 0/Progestins; 630-56-8/17-alpha-hydroxy-progesterone caproate
Comments/Corrections
Erratum In:
Obstet Gynecol. 2014 Mar;123(3):669

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Validation of the joint commission exclusion criteria for elective early-term delivery.
Next Document:  Maternal vitamin D status and small-for-gestational-age offspring in women at high risk for preeclam...